Sanofi invests heavily in multiple myeloma pipeline
The Paris-based Big Pharma has signed a license agreement with Californian biotech Eureka Therapeutics and Memorial Sloan Kettering Cancer Center,...
Yet another blow to Merck’s cancer hopeful
Merck KGaA announced it has decided to discontinue the Phase II INTR@PID BTC 055 study evaluating bintrafusp alfa with gemcitabine plus cisplatin in...
Foundation launches Harvard research hub
The foundation and the Broad Institute have joined up to launch the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, an initiative...
Bio-Me raises NOK10m
Both, existing and new investors participated in the financing round, with new investors contributing the majority of the capital. The company said...
Boehringer walks away from CureVac deal
CureVac announced the termination of the 2014 programme BI1361849 in its financial report. Seven years ago, CureVac had received €35m upfront, with...
Touchlight extends funding round to boost DNA vector manufacture
The company said it will use the funds to expand production capacity for its enzymatically produced synthetic (“doggybone DNA™”) DNA vector, dbDNA™...
Boehringer Ingelheim: Takeover in immunooncology
Abexxa focusses on the development of specific antibodies to intracellular antigens presented by the non-classical MHC Class I molecule, HLA-E (human...